The newest research about living with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (ME/CFS)/fibromyalgia, with personal observations (the most pertinent parts of long articles will be highlighted for the reader)
Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia
Theravance, Inc. THRX -0.80% today announced positive results from a Phase 2 study of TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor (NSRI), in patients with fibromyalgia (FM).
"We are very pleased with the positive results of our Phase 2 study of TD-9855 in patients with fibromyalgia," said Mathai Mammen, M.D., Ph.D., Senior Vice President of Research and Development. "Patients with fibromyalgia have a clear unmet medical need: a medicine that will treat their pain and address other symptoms of this disorder, including fatigue and cognitive impairment. In this Phase 2 study, TD-9855 demonstrated a beneficial impact on symptoms important to patients with fibromyalgia."
This drug is no different than other drugs in this class known as selective serotonin, norepinephrine reuptake inhibitors (SSNRI) which include Savella, Cymbalta, and the original SSNRI, Effexor.
These drugs are supposed to help a person re-uptake and use the serotonin (calming brain hormone) and norepinephrine (stimulating brain hormone) more effectively.
Looking at the most recent overhyped SSNRI drug, , which Savella was based on two clinical trials involving 2,084 fibromyalgia patients (1,460 on Savella and 624 on placebo) we read this -